CLOROX CO /DE/ Form 10-Q February 05, 2013

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

THE SECURITIES EXCHANGE ACT OF 1934

(Mark One)

Х

For the quarterly period ended December 31, 2012.

to

OR

0

For the transition period from

Commission File Number: 1-07151

THE CLOROX COMPANY

(Exact name of registrant as specified in its charter) **31-0595760** (I.R.S. Employer Identification No.)

Delaware

(State or other jurisdiction of incorporation or organization)

1221 Broadway Oakland, California (Address of principal executive offices)

94612-1888 (Zip code)

(510) 271-7000

(Registrant's telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes b No c

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes b No c

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act:

Edgar Filing: CLOROX CO /DE/ - Form 10-Q

Large accelerated filer bAccelerated filer cNon-accelerated filer cSmaller Reporting Company cIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes cNo b

As of January 31, 2013, there were 130,962,056 shares outstanding of the registrant s common stock (\$1.00 par value).

The Clorox Company

	Page No.
PART I. Financial Information	3
Item 1. Financial Statements	<u>3</u>
Condensed Consolidated Statements of Earnings and Comprehensive Income	
for the Three and Six Months Ended December 31, 2012 and 2011	<u>3</u>
Condensed Consolidated Balance Sheets as of December 31, 2012 and June 30, 2012	<u>4</u>
Condensed Consolidated Statements of Cash Flows for the Six Months Ended	
December 31, 2012 and 2011	5
Notes to Condensed Consolidated Financial Statements	6
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	<u>6</u> <u>17</u>
Item 3. Quantitative and Qualitative Disclosures about Market Risk	<u>28</u>
Item 4. Controls and Procedures	<u>28</u> <u>28</u>
PART II. Other Information	
Item 1.A. Risk Factors	<u>29</u> <u>29</u>
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	<u>29</u> 30
Item 6. Exhibits	<u>30</u>

PART I FINANCIAL INFORMATION

Item 1. Financial Statements

The Clorox Company Condensed Consolidated Statements of Earnings and Comprehensive Income (Unaudited) (In millions, except share and per share amounts)

	Three Months Ended									
					12/31/2011			31/2012		51/2011
Net sales	\$	1,325	\$	1,221	\$	2,663	\$	2,526		
Cost of products sold		762		714		1,526		1,473		
Gross profit		563		507		1,137		1,053		
	_									
Selling and administrative expenses		204		184		399		374		
Advertising costs	_	116		115		238		233		
Research and development costs		31		29		61		57		
Interest expense		33		30		66		59		
Other income, net		(9)		(6)		(9)		(12)		
Earnings before income taxes		188		155		382		342		
Income taxes		65		50		126		107		
Net earnings	\$	123	\$	105	\$	256	\$	235		
Net earnings per share										
Basic	\$	0.94	\$	0.79	\$	1.96	\$	1.78		
Diluted	\$	0.93	\$	0.79	\$	1.94	\$	1.76		
Weighted average shares outstanding (in thousands)										
Basic		130,991		131,112		130,630		131,540		
Diluted		132,444		132,358		132,120		133,022		
Dividend declared per share	\$	0.64	\$	0.60	\$	1.28	\$	1.20		
Comprehensive income	\$	116	\$	96	\$	276	\$	162		

See Notes to Condensed Consolidated Financial Statements

The Clorox Company Condensed Consolidated Balance Sheets (In millions, except share and per share amounts)

	12/31/2012 (Unaudited)		6/30/2012		
ASSETS					
Current assets	•		¢	2/7	
Cash and cash equivalents	\$	445	\$	267	
Receivables, net		511		576	
Inventories, net		444		384	
Other current assets		152		149	
Total current assets		1,552		1,376	
Property, plant and equipment, net of accumulated depreciation		1.051		1 001	
of \$1,779 and \$1,804, respectively		1,051		1,081	
Goodwill		1,119		1,112	
Trademarks, net		556		556	
Other intangible assets, net		79		86	
Other assets		145	_	144	
Total assets	\$	4,502	\$	4,355	
	_				
LIABILITIES AND STOCKHOLDERS EQUITY (DEFICIT)					
Current liabilities		-	¢	200	
Notes and loans payable	\$	5	\$	300	
Current maturities of long-term debt	_	500		850	
Accounts payable		365		412	
Accrued liabilities	_	493		494	
Income taxes payable		10		5	
Total current liabilities		1,373		2,061	
Long-term debt		2,169		1,571	
Other liabilities		788		739	
Deferred income taxes		116		119	
Total liabilities		4,446		4,490	
Contingencies					
Contrigencies					
Stockholders equity (deficit)					
Preferred stock: \$0.001 par value; 5,000,000 shares authorized; none					
issued or outstanding		-		-	
Common stock: \$1.00 par value; 750,000,000 shares authorized; 158,741,461 shares					
issued at both December 31, 2012 and June 30, 2012; and 130,862,243 and 129,562,082					
shares outstanding at December 31, 2012 and June 30, 2012, respectively		159		159	
Additional paid-in capital		644		633	
Retained earnings		1,430		1,350	
Treasury shares, at cost: 27,879,218 and 29,179,379 shares		1,100		1,000	
at December 31, 2012 and June 30, 2012, respectively		(1,801)		(1,881)	
Accumulated other comprehensive net losses		(376)		(396)	
Stockholders equity (deficit)		56		(135)	
Total liabilities and stockholders equity (deficit)	\$	4.502	\$	4,355	
rotar naomnes and stockholders equity (deficit)	Э	4,302	¢	4,333	

See Notes to Condensed Consolidated Financial Statements

Edgar Filing: CLOROX CO /DE/ - Form 10-Q

Table of Contents

The Clorox Company Condensed Consolidated Statements of Cash Flows (Unaudited) (Dollars in millions)

	Six Months Ended 12/31/2012 12/3			12/31/	31/2011		
Operating activities:							
Net earnings	\$	25	6	\$	235	;	
Adjustments to reconcile earnings from operations:							
Depreciation and amortization		9			89		
Share-based compensation		13	8		11		
Deferred income taxes		(.	2)		3	5	
Other		13			(29)	
Changes in:						_	
Receivables, net		7	1		35	;	
Inventories, net		(5)	7)		(65	i)	
Other current assets			3		-		
Accounts payable and accrued liabilities		(5	9)		(100))	
Income taxes payable		(3	8)		(11)	
Net cash provided by operations		32:	5		168	;	
Investing activities:							
Capital expenditures		(10)	2)		(82	<u>')</u>	
Proceeds from sale-leaseback, net of transaction costs		10	8		-	í –	
Businesses acquired, net of cash acquired			-		(93	5)	
Other		-			12		
Net cash provided by (used for) investing activities			6		(163	5)	
Financing activities:							
Notes and loans payable, net		(29:	5)		14	ŀ	
Long-term debt borrowings, net of issuance costs		593			297	1	
Long-term debt repayments		(350)		_		
Treasury stock purchased		_	,		(158)	
Cash dividends paid		(167)		(159	Ś	
Issuance of common stock for employee stock plans and other		64)		44)	
)				
Net cash (used for) provided by financing activities		(155)		38		
Effect of exchange rate changes on cash and cash equivalents		2			(5)	
Net increase in cash and cash equivalents		178			38		
Cash and cash equivalents:		2/-			0.50		
Beginning of period	^	267		.	259		
End of period	\$	445		\$	297		

See Notes to Condensed Consolidated Financial Statements

The Clorox Company Notes to Condensed Consolidated Financial Statements (In millions, except share and per share amounts)

NOTE 1. INTERIM FINANCIAL STATEMENTS

Basis of Presentation

The unaudited interim condensed consolidated financial statements for the three and six months ended December 31, 2012 and 2011, in the opinion of management, reflect all adjustments (consisting of normal recurring accruals) necessary for a fair presentation of the consolidated results of operations, financial position and cash flows of The Clorox Company and its subsidiaries (the Company) for the periods presented. The results for the interim period ended December 31, 2012, are not necessarily indicative of the results that may be expected for the fiscal year ending June 30, 2013, or for any future period.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) have been omitted or condensed pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). The information in this report should be read in conjunction with the Company s Annual Report on Form 10-K filed with the SEC for the fiscal year ended June 30, 2012, which includes a complete set of footnote disclosures, including the Company s significant accounting policies.

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts and related disclosures. Actual results could differ materially from estimates and assumptions made.

NOTE 2. INVENTORIES, NET

Inventories, net, consisted of the following as of:

	12/31/2012		6/30	/2012
Finished goods	\$	334	\$	307
Raw materials and packaging		157		120
Work in process		5		4
LIFO allowances		(42)		(37)
Allowances for obsolescence		(10)		(10)
Total	\$	444	\$	384

NOTE 3. OTHER LIABILITIES

Other liabilities consisted of the following as of:

	12/31/2012		6/30	/2012
Employee benefit obligations	\$	325	\$	312
Venture agreement net terminal obligation		283		281
Taxes		68		82
Other		112		64
Total	\$	788	\$	739

In December 2012, the Company completed a sale-leaseback transaction under which it sold its general office building in Oakland, Calif. to an unrelated party for net proceeds of \$108 and entered into a 15-year operating lease agreement with the buyer for a portion of the building. The Company recorded a liability of \$52 (\$3 of which is included in accrued liabilities) for the portion of the total gain on the sale that is equivalent to the present value of the lease payments and will amortize such amount to earnings ratably over the lease term. The Company recorded a gain upon sale of \$6, which is included in other income, net, in the condensed consolidated statements of earnings and comprehensive income.

NOTE 4. DEBT

In October 2012, \$350 in senior notes with an annual fixed interest rate of 5.45% became due and was paid. The repayment was funded with a portion of the proceeds from the issuance of \$600 in senior notes in September 2012 with an annual fixed interest rate of 3.05%. The notes were issued under the Company s existing shelf registration statement, with interest payable semi-annually in March and September and a maturity date of September 15, 2022. The remaining net proceeds were used to repay commercial paper. The notes rank equally with all of the Company s existing and future senior indebtedness.

NOTE 5. NET EARNINGS PER SHARE

The following is the reconciliation of the weighted average number of shares outstanding (in thousands) used to calculate basic net earnings per share (EPS) to those used to calculate diluted net EPS:

	Three M	Ionths Ended	ded Six Months En		
	12/31/2012	12/31/2011	12/31/2012	12/31/2011	
Basic	130,991	131,112	130,630	131,540	
Dilutive effect of stock options and other	1,453	1,246	1,490	1,482	
Diluted	132,444	132,358	132,120	133,022	

During the three and six months ended December 31, 2012, the Company included all stock options to purchase shares of the Company s common stock in the calculations of diluted net EPS because the average market price of all outstanding grants was greater than the exercise price.

During the three and six months ended December 31, 2011, the Company did not include stock options to purchase approximately 3.8 million shares and 1.9 million shares, respectively, of the Company s common stock in the calculations of diluted net EPS because their exercise price was greater than the average market price, making them anti-dilutive.

NOTE 6. COMPREHENSIVE INCOME

Comprehensive income is defined as net earnings and other changes in stockholders equity (deficit) from transactions and other events from sources other than stockholders. Comprehensive income was as follows:

	Three Month	is Ended	Six Months Ended		
	12/31/2012	12/31/2012 12/31/2011			
Net earnings	\$ 123	105	\$ 256	235	
Other comprehensive income (losses), net of tax:					
Foreign currency translation adjustments	(9)	2	18	(37)	
Net d					